BIOMOLECULAR ANALYSIS USING LIQUID CRYSTALS

描述(由申请人提供)：威斯康星大学生物工程研究伙伴关系(UW-BRP)正在开发新的分子分析工具，以确定和验证生物终点，从而可以更准确和快速地评估新型抗癌药物的活性，以确定其分子机制(S)和临床相关性。这项工作的重点是表皮生长因子受体(EGFR)，因为它的过度表达和突变与一些最无法治愈的癌症密切相关。然而，这些工具的通用性足以适用于其他关键的信号分子。尽管许多现有筛查的基础限制了它们的应用于受体或其他信号分子的浓缩制剂的体外分子分析，但UW-BRP试图建立工具的原理，这些工具也可以应用于培养细胞的样本分析，以及来自异种摄影和自发性肿瘤组织的活组织分析。这种能力最终将实现一种跨越分子、细胞和组织水平的基本方法，并将用于基础研究以及动物和人类临床试验。在过去的4年里，UW-BRP确定了基于液晶的分子分析工具的关键分析特征，并展示了关于EGFR表达和激活(磷酸化)以及小分子(在膜提取物和细胞裂解物等复杂样品中)抑制EGFR酪氨酸激酶活性的报道。本建议寻求继续支持具有化学和生物工程、化学和生物化学以及生物分子和生物医学科学方面不同专长的多学科研究人员团队，以通过整合下列领域的进展来进一步发展这一广泛适用的生物分析方法：a)鉴定和优化识别细胞裂解物中关键EGFR突变体表位的统一固定化单链抗体；b)整合液晶分析方法和样品制备，以使用小样本(少数细胞)定量表达、激活和抑制野生型和突变型EGFR；以及c)研究参与致癌过程中的关键细胞信号蛋白。具体地说，UW-BRP分子分析工具将在一项研究中与传统方法进行比较，该研究将a)快速和灵敏地评估生物样本中野生型和突变型人EGFR的水平和活性，b)检验野生型和致癌形式的EGFR将显示出不同的抑制剂特异性的假设，以及c)评估在体外有效抑制EGF介导的事件的药物是否也将在细胞培养中显示出拮抗EGFR表达和/或活性的能力。从长远来看，这些新工具应该有助于评估抗癌药物的分子机制和后果，从而促进从基础生物学到临床疗效评估的研究。公众

DESCRIPTION (provided by applicant): The University of Wisconsin Bioengineering Research Partnership (UW-BRP) is developing new molecular analysis tools to identify and validate biological endpoints whereby the activity of novel anti-cancer agents can be more accurately and rapidly evaluated as to their molecular mechanism(s) and clinical relevance. The work is focused on epidermal growth factor receptor (EGFR), given that its overexpression and mutation has been closely-associated with some of the most incurable cancers. However, the tools are sufficiently versatile to be applicable to other key signaling molecules. Whereas the basis of many existing screens restricts their application to in vitro molecular analyses of enriched preparations of receptors or other signaling molecules, the UW-BRP seeks to establish principles for tools that can also be applied to the analysis of samples from cultured cells, and from biopsies of xenographs and spontaneous tumor tissues. This capability will ultimately enable a fundamental approach that will span the molecular, cellular and tissue levels and will be used in both basic research and in animal and human clinical trials. Over the past 4 years, the UW-BRP has defined key analytic characteristics of liquid crystal-based tools for molecular analysis, and demonstrated reporting of EGFR expression and activation (phosphorylation) as well as inhibition of EGFR tyrosine kinase activity by small molecules (in complex samples such as membrane extracts and cell lysates). The present proposal seeks continued support for the multi-disciplinary team of researchers with diverse expertise in chemical and biological engineering, chemistry and biochemistry, and the biomolecular and biomedical sciences to develop further this broadly-applicable bioanalytical approach via integration of advances in the following areas: a) identification and optimization of uniformly immobilized, single chain antibodies that recognize epitopes of key EGFR mutants in cell lysates, b) integration of liquid crystal-based analytic methodologies and sample preparation for quantification of expression, activation and kinase inhibition of wild-type and mutant EGFRs using small samples (a few cells), and c) the investigation of key cell signaling proteins that participate in processes associated with carcinogenesis. Specifically, the UW-BRP molecular analysis tools will be compared to conventional methods in a study that will a) rapidly and sensitively assess the levels and activity of wild-type and mutant human EGFRs in biological samples, b) test the hypothesis that wild-type and oncogenic forms of the EGFR will exhibit differential inhibitor specificity, and c) assess if agents that potently inhibit EGF-mediated events in vitro will also exhibit a capacity to antagonize EGFR expression and/or activity in cell culture. In the long term, these new tools should be useful for the assessment of the molecular mechanisms and consequences of anti-cancer agents, thereby facilitating their research from basic biology through to clinical assessment of efficacy. PUBLIC